Leman Biotech Initiates Phase 1 Clinical Trial of Metabolically Enhanced CAR-T 'Meta10-19' for Lupus.
Next-Generation CAR-T Technology with Metabolic Reprogramming
Meta10-19, jointly developed by Leman Biotech and Zhejiang University, is a metabolically armed CD19-targeting CAR-T cell therapy that enhances therapeutic efficacy by manipulating the metabolic pathways of T cells. Conventional CAR-T therapies face limitations in autoimmune disease patients due to metabolic stress in the harsh in vivo environment, leading to rapid T cell death and reduced efficacy. To overcome this, Meta10-19 employs metabolic reprogramming via the immunomodulatory cytokine interleukin-10 (IL-10), significantly improving cell survival and immune activation.
Phase 1 Clinical Trial for Autoimmune Disease Lupus
The ongoing Phase 1 clinical trial (NCT06711146) evaluates the safety and efficacy of Meta10-19 in patients with moderate to severe active systemic lupus erythematosus (SLE). Recruitment began in December 2024, with a primary completion target set for December 2026. The ultimate goal is to completely target and eliminate pathological B cells, effectively resetting the immune system. Since lupus, a chronic autoimmune disease, arises from abnormal B cell activation, the well-established mechanism of CD19 CAR-T cells is expected to be highly effective in this context.
Innovative Dosing Approach Without Lymphodepleting Chemotherapy
A key technological differentiator of Meta10-19 is its exploration of a non-chemotherapy protocol that eliminates the need for lymphodepleting conditioning chemotherapy prior to administration. Traditional CAR-T therapies require high-toxicity chemotherapies such as fludarabine and cyclophosphamide to facilitate cell engraftment, which carry significant side effect risks. However, Meta10-19's metabolic enhancement allows for robust survival and proliferation even with minimal cell doses (0.1% to 1% of conventional doses), demonstrating the potential for effective treatment without chemotherapy.
Potential Structural Shift in the Autoimmune Disease Market
The current lupus treatment market is valued at approximately $3.35 billion annually, with existing biologics such as GSK's Benlysta and AstraZeneca's Saphnelo dominating the landscape. However, these standard-of-care therapies only delay or alleviate symptoms, requiring patients to take medication for life. In contrast, a successful CAR-T cell therapy that can achieve curative outcomes with a single infusion could become a revolutionary game-changer, fundamentally altering the market dynamics of autoimmune disease treatments.
The initiation of the Phase 1 clinical trial for Meta10-19 in lupus represents a significant attempt to reset the current treatment paradigm dominated by immunosuppressive drugs, drawing considerable attention from the industry and investors. With the global systemic lupus erythematosus (SLE) market estimated at around $3.35 billion in 2026, the metabolic enhancement technology of Meta10-19 is gaining high credibility among researchers for its ability to eliminate the side effects of traditional chemotherapy conditioning while ensuring both safety and patient convenience. In the short term, the clinical safety and B cell elimination data from the ultra-low-dose, non-chemotherapy-based dosing protocol will be key milestones. In the medium to long term, the ability to demonstrate efficacy differentiation from early-stage CD19 CAR-T competitors such as Kyverna Therapeutics' KYV-101 and Cabaletta Bio's CABA-201 will determine whether Meta10-19 can establish leadership in the autoimmune disease cell therapy market.
Source: ClinicalTrials.gov (api_ct)